The Sexually Transmitted Disease (STD) Morbidity online databases on CDC WONDER contain case reports reported from the 50 United States and D.C., Puerto Rico, Virgin Islands and Guam. The online databases report the number of cases and disease incidence rates by year, state, disease, age, sex of patient, type of STD, and area of report, since 1984. Data are updated annually. Data are produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).

The Sexually Transmitted Disease (STD) Morbidity online databases on CDC WONDER contain case reports reported from the 50 United States and D.C., Puerto Rico, Virgin Islands and Guam. The online databases report the number of cases and disease incidence rates by year, state, disease, age, sex of patient, type of STD, and area of report. Data are produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).

This dataset tracks the updates made on the dataset "CDC WONDER: Sexually Transmitted Disease (STD) Morbidity" as a repository for previous versions of the data and metadata.

This dataset contains the analysis of surveillance data on Sexually transmitted diseases (STDs) diagnosis for all states in the US. The data was collected from the CDC Division of STD Prevention program from reporting forms and electronic data of the National Electronic Telecommunications System for Surveillance (NETSS). This dataset combines age, sex and races and covers Chlamydia, Gonorrhea and different presentations of Syphilis.

In 2023, there were an estimated 1.03 million cases of chlamydia among women in the United States and around 610,445 cases among men. Furthermore, that year, there were around 378,428 cases of gonorrhea among men and 221,176 cases among women. Despite the dangers of sexually transmitted diseases (STDs) being more commonplace and testing and contraception, for the most part, widely accessible in the United States, rates of chlamydia, gonorrhea, and syphilis, have all risen in recent years. Chlamydia in the United States According to the CDC, chlamydia is the most commonly reported bacterial sexually transmitted infection (STI) in the United States. In 2023, there were around 492 cases of chlamydia per 100,000 population, a substantial increase from a rate of 289 per 100,000 population in the year 2002. Those aged 20 to 24 had the highest rates of chlamydia in the U.S. in 2023. Although chlamydia often has no symptoms, it can cause serious health problems if left untreated, one of the reasons those who are sexually active should be regularly tested for STDs. Once diagnosed, chlamydia can be easily cured with antibiotics. Gonorrhea Rates of gonorrhea in the United States decreased after reaching a peak in the 1980s but began to rise again over the past decade. In 2023, there were 179.5 cases of gonorrhea per 100,000 population in the United States, compared to 98 cases per 100,000 population in the year 2009. While rates of chlamydia in the U.S. tend to be higher among women than men, rates of gonorrhea are higher among men, with those aged 20 to 24 the most affected. Like chlamydia, gonorrhea can be cured with medicine but can cause serious and permanent health problems if left untreated.

This dataset details newly diagnosed STD Cases and Rate Per 100,000.

This dataset tracks the updates made on the dataset "CDC WONDER: Sexually Transmitted Disease (STD) morbidity" as a repository for previous versions of the data and metadata.

The AIDS Public Information Data Set (APIDS) for years 1981-2002 on CDC WONDER online database contains counts of AIDS (Acquired Immune Deficiency Syndrome) cases reported by state and local health departments, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarter-year of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS). Data are produced by the US Department of Health and Human Services (US DHHS), Public Health Service (PHS), Centers for Disease Control and Prevention (CDC), National Center for HIV, STD and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention (DHP).

NNDSS - Table III. Tuberculosis - 2017.This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States will exclude counts from US territories. Footnote: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Min: Minimum. Max: Maximum. * Case counts for reporting year 2016 and 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf Data for TB are displayed quarterly.

U.S. states ranked by cases of Chlamydia, gonorrhea, and primary and secondary syphilis reported. Data Source: Centers for Disease Control and Prevention Surveillance Reports 2000-2015 (http://www.cdc.gov/std/stats11/default.htm)

U.S. counties ranked nationally by cases of primary and secondary syphilis reported. Data Source: Centers for Disease Control and Prevention 2000-2015 Surveillance Report (http://www.cdc.gov/STD/publications/default.htm)

NNDSS - Table II. Tuberculosis - 2019. This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying WONDER data. Data on United States will exclude counts from US territories. Footnote: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Min: Minimum. Max: Maximum. * Case counts for reporting year 2018 and 2019 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf † Data for TB are displayed quarterly.

This dataset contains the analysis of surveillance data on viral hepatitis for all states in the US. The data was collected from the CDC Division of Sexually transmitted diseases (STDs) Prevention program from reporting forms and electronic data of the National Electronic Telecommunications System for Surveillance (NETSS). This dataset combines age, sex and races.

This study used a mixed-methods approach to identify provider- and clinic-level barriers and facilitators in the latent tuberculosis infection (LTBI) care cascade at community health clinics. This included both qualitative and quantitative data collection.

The Online Tuberculosis Information System (OTIS) on CDC WONDER contains information on verified tuberculosis (TB) cases reported to the Centers for Disease Control and Prevention (CDC) by state health departments, the District of Columbia and Puerto Rico since 1993. These data were extracted from the CDC national TB surveillance system. OTIS reports case counts, incidence rates, population counts, percentage of cases that completed therapy within 1 year of diagnosis, and percentage of cases tested for drug susceptibility. Data for 22 variables are included in the data set, including: age groups, race / ethnicity, sex, vital status, year reported, state, metropolitan area, several patient risk factors, directly observed therapy, disease verification criteria and multi-drug resistant TB. Each year these data are updated with an additional year of cases plus revisions to cases reported in previous years. OTIS is produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).

This dataset contains the analysis of surveillance data on tuberculosis for all states in the US. The data was collected from the CDC Division of Sexually transmitted diseases (STDs) Prevention program from reporting forms and electronic data of the National Electronic Telecommunications System for Surveillance (NETSS). This dataset combines age, sex and races.

This was a sub study of a larger study that had a mixed methods approach focused on identifying barriers and facilitators to increasing testing and treatment of latent tuberculosis infection at community health clinics and tuberculosis (TB) clinics. This sub study focuses on the patient perspective on the barriers and facilitators to TB prevention and care.

NNDSS - Table I. infrequently reported notifiable diseases - 2014.In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnote:-: No reported cases N: Not reportable NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. * Case counts for reporting year 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. ��� Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. �� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the Arboviral diseases, STD data, TB data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/document/SRCA_FINAL_REPORT_2006-2012_final.xlsx. �� Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Data for H. influenzae (all ages, all serotypes) are available in Table II. ��ʉ�� Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Please refer to the MMWR publication for weekly updates to the footnote for this condition. ���� Please refer to the MMWR publication for weekly updates to the footnote for this condition. ���� Data for meningococcal disease (all serogroups) are available in Table II. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ��ʉ�ʉ�� Please refer to the MMWR publication for weekly updates to the footnote for this condition. ������ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ������ Please refer to the MMWR publication for weekly updates to the footnote for this condition. See Table II for Dengue Hemorrhagic Fever.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

This study focused on describing and quantifying the steps in the tuberculosis (TB) prevention cascade of care within health department clinics. This included better understanding the proportions of patients with latent TB infection who are identified, offered treatment, accept treatment, and complete treatment.

This was a head-to-head comparison of three FDA-approved tests for TB infection (Tuberculin Skin Test, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB) in populations at high risk of latent TB infection and/or progression to TB disease.